Clinical trial
Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy
NCT00048880 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 5, 2002
- Completion date
- July 2, 2008
- Enrollment
- 9 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.